PeproMene Bio, Inc. Announces Complete Response of First Patient Treated in Its Phase 1 B-Cell Non-Hodgkin’s Lymphoma (B-NHL) Clinical Study of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope

Irvine, Calif., December 21, 2022 /PRNewswire/ — PeproMene Bio, Inc., a clinical-stage biotechnology company developing new therapies to treat cancer and immune disorders, today announced that the first patient treated in its Phase 1 is non-Hodgkin’s lymphoma a relapsed or refractory B-cell (r/r B-NHL) PMB-CT01 (BAFFR-CAR T-cell) clinical study achieved complete response at 1 month post-treatment. The trial is taking place at City of Hope, one of the largest cancer research and treatment organizations in the the United States.

Take advantage of the new CAR-T therapy

Take advantage of the new CAR-T therapy

During the first month of treatment, the patient experienced only low-grade treatment-emergent toxicities, including grade 1 cytokine release syndrome (“CRS”) with complete recovery, and no immune effector cell-associated neurotoxicity syndrome (” ICANS”). “This patient with mantle cell lymphoma has been refractory to several prior lines of treatment, including chemoimmunotherapy, BTK inhibitor, Venetoclax, and CD19-CAR T therapy. We are delighted to see deep complete remission that is negative for minimal residual disease “, he has declared Elizabeth BuddhaMD, Ph.D., associate professor in the City of Hope, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation and principal investigator of this single-site dose escalation study (NCT05370430).

“Despite the high initial efficacy of CD19-CAR T-cell treatment for B-cell lymphoma and leukemia, there is a significant unmet medical need for those patients who unfortunately relapse,” he said. Larry W.Kwak, MD, Ph.D., vice president and deputy director of the City of Hope Comprehensive Cancer Center and scientific founder of PeproMene and remunerated chair of its scientific advisory board. Kwak has a stake in PeproMene. “Because BAFF-R is a novel tumor target for B-cell malignancies, I hope BAFFR-CAR T therapy offers a new, clinically meaningful option for those patients.”

“The acceptable safety profile and early complete response of our first treated B-NHL patient PMB-CT01 is an unprecedented milestone in the development and evaluation of PMB-CT01. These initial clinical results are supported by data from preclinical research from City of Hope published in Science Translational Medicine in 2019, which demonstrated that PMB-CT01 (BAFFR-CAR T Cells) can overcome CD19 antigen loss in B-cell malignancies,” he said Hazel ChengPh.D., COO of PeproMene.

About PMB-CT01
PMB-CT01 is a first-in-class BAFFR-targeted autologous CAR T cell therapy. BAFF-R (B Cell Activating Factor Receptor), a member of the tumor necrosis factor (TNF) receptor superfamily, is the major receptor for BAFF expressing almost exclusively on B cells. Because BAFF-R signaling promotes normal B-cell proliferation and appears to be necessary for B-cell survival, it is unlikely that tumor cells could escape immune responses through loss of BAFF-R antigen. This unique feature makes BAFF-R CAR T therapy a great potential treatment of B-cell malignancies. BAFF-R CAR-T was constructed using anti-BAFF-R scFv (single-chain fragment variable) antibodies with the domains generation signaling cells containing CD3ζ and 4-1BB. Our research has found that BAFFR-CAR T cells kill human lymphomas and leukemias both in vitro and in animal models. PeproMene has licensed the intellectual property related to PMB-CT01, from City of Hope.

About PeproMene
PeproMene is a clinical-stage biotechnology company in Irvine, Calif the development of new therapies for the treatment of tumors and immune disorders. PeproMene’s lead candidate, PMB-CT01 (BAFFR-CAR T Cells) is currently under investigation for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL; NCT04690595) and B-cell non-Hodgkin’s lymphoma (B-NHL; NCT05370430 ) in Phase 1 clinical trials. PeproMene is also developing BAFFR Bispecific T Cell Engager and BAFFR-CAR NK cells. For more information, please contact Hazel ChengPhD of PeproMene Bio Inc. at [email protected] or visit

SOURCE PeproMene Bio, Inc.

Add a Comment

Your email address will not be published. Required fields are marked *